Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and DexamethasoneJames Croft, Martin Kaiser, Charlotte Pawlyn et al.|Blood|2018Cited by 8
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitorSamantha Hinsley, Gordon Cook, Katrina Walker et al.|Trials|2020Cited by 4
Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven TrialJames Croft, Martin Kaiser, Andrew Hall et al.|Blood|2018Cited by 2